Syros Pharmaceuticals, Inc. Common Stock
SYRS
SYRS was delisted on the 19th of March, 2025.
75 hedge funds and large institutions have $112M invested in Syros Pharmaceuticals, Inc. Common Stock in 2024 Q1 according to their latest regulatory filings, with 22 funds opening new positions, 21 increasing their positions, 7 reducing their positions, and 5 closing their positions.
5,300% more call options, than puts
Call options by funds: $162K | Put options by funds: $3K
340% more first-time investments, than exits
New positions opened: 22 | Existing positions closed: 5
200% more repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 7
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
29% more funds holding
Funds holding: 58 → 75 (+17)
24% less capital invested
Capital invested by funds: $147M → $112M (-$34.9M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$2.96M |
| 2 |
KCM
Kennedy Capital Management
St Louis,
Missouri
|
+$2.8M |
| 3 |
Walleye Capital
New York
|
+$1.97M |
| 4 |
Millennium Management
New York
|
+$1.81M |
| 5 |
Goldman Sachs
New York
|
+$1.43M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BOCH
Blue Owl Capital Holdings
New York
|
-$7.97M |
| 2 |
TCM
Tang Capital Management
San Diego,
California
|
-$662K |
| 3 |
EI
EAM Investors
Solana Beach,
California
|
-$654K |
| 4 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
-$547K |
| 5 |
6CM
683 Capital Management
New York
|
-$284K |
SYRS Hedge Fund Activity: Q1 2024 in Review
75 of the 6,943 institutional investors tracked by Wall St. Rank reported a position in Syros Pharmaceuticals, Inc. Common Stock (SYRS) for Q1 2024, worth a combined $112M — down 24% from $147M a quarter earlier.
Buyers outnumbered sellers: 22 funds opened new SYRS positions and 5 closed out — a net gain of 17 holders — while 21 added to existing stakes and 7 trimmed.
The largest buyer was Opaleye Management, adding an estimated $2.96M. The largest seller was Blue Owl Capital Holdings, cutting an estimated $7.97M.
- 75 institutional investors held Syros Pharmaceuticals, Inc. Common Stock (SYRS) as of Q1 2024, up from 58 in Q4 2023.
- Funds reported $112M of Syros Pharmaceuticals, Inc. Common Stock stock for Q1 2024, down 24% quarter-over-quarter.
- 22 funds opened new Syros Pharmaceuticals, Inc. Common Stock positions in Q1 2024 and 5 closed out, a net change of +17 holders.
- The largest Syros Pharmaceuticals, Inc. Common Stock buyer in Q1 2024 was Opaleye Management, an estimated $2.96M added.
- The largest Syros Pharmaceuticals, Inc. Common Stock seller in Q1 2024 was Blue Owl Capital Holdings, an estimated $7.97M sold.
Based on aggregated 13F filings for Q1 2024.